{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T20:20:42Z","timestamp":1758054042692,"version":"3.44.0"},"reference-count":118,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Disease-a-Month"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1016\/j.disamonth.2022.101349","type":"journal-article","created":{"date-parts":[[2022,3,22]],"date-time":"2022-03-22T09:20:18Z","timestamp":1647940818000},"page":"101349","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Oral immune-mediated disorders with malignant potential\/association: An overview"],"prefix":"10.1016","volume":"69","author":[{"given":"Shankargouda","family":"Patil","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pradeep Kumar","family":"Yadalam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jagadish","family":"Hosmani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zafar Ali","family":"Khan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zeeshan Heera","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vidya Gurram","family":"Shankar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kamran Habib","family":"Awan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.disamonth.2022.101349_bib0001","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1111\/ijd.12681","article-title":"Immune-mediated diseases: what can be found in the oral cavity?","volume":"54","author":"Bascones-Mart\u00ednez","year":"2015","journal-title":"Int J Dermatol"},{"issue":"14","key":"10.1016\/j.disamonth.2022.101349_bib0002","doi-asserted-by":"crossref","first-page":"7224","DOI":"10.3390\/ijerph18147224","article-title":"Association of microbiome with oral squamous cell carcinoma: a systematic review of the metagenomic studies","volume":"18","author":"Su Mun","year":"2021","journal-title":"Int J Environ Res Public Health"},{"key":"10.1016\/j.disamonth.2022.101349_bib0003","doi-asserted-by":"crossref","first-page":"6705","DOI":"10.2147\/CMAR.S283204","article-title":"Therapeutic options in unresectable oral squamous cell carcinoma: a systematic review","volume":"13","author":"Madera","year":"2021","journal-title":"Cancer Manag Res"},{"issue":"5","key":"10.1016\/j.disamonth.2022.101349_bib0004","doi-asserted-by":"crossref","first-page":"405","DOI":"10.3390\/medicina57050405","article-title":"Association between IL-8 (-251T\/A) and IL-6 (-174G\/C) polymorphisms and oral cancer susceptibility: a systematic review and meta-analysis","volume":"57","author":"Rezaei","year":"2021","journal-title":"Medicina (B Aires)"},{"issue":"12","key":"10.1016\/j.disamonth.2022.101349_bib0005","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1089\/jir.2019.0070","article-title":"Evaluation of serum and salivary interleukin-6 and interleukin-8 levels in oral squamous cell carcinoma patients: systematic review and meta-analysis","volume":"39","author":"Rezaei","year":"2019","journal-title":"J Interf Cytokine Res"},{"issue":"10","key":"10.1016\/j.disamonth.2022.101349_bib0006","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1111\/j.1600-0714.2007.00582.x","article-title":"Nomenclature and classification of potentially malignant disorders of the oral mucosa","volume":"36","author":"Warnakulasuriya","year":"2007","journal-title":"J Oral Pathol Med"},{"issue":"6","key":"10.1016\/j.disamonth.2022.101349_bib0007","doi-asserted-by":"crossref","first-page":"3223","DOI":"10.21873\/anticanres.12587","article-title":"Potentially malignant oral disorders and cancer transformation","volume":"38","author":"Ganesh","year":"2018","journal-title":"Anticancer Res"},{"issue":"8","key":"10.1016\/j.disamonth.2022.101349_bib0008","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.medcle.2017.09.013","article-title":"Treatment of oral lichen planus. Systematic review and therapeutic guide","volume":"149","author":"Garc\u00eda-Pola","year":"2017","journal-title":"Med Cl\u00ednica (English Ed."},{"issue":"8","key":"10.1016\/j.disamonth.2022.101349_bib0009","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1056\/NEJMcp1103641","article-title":"Lichen planus","volume":"366","author":"Le Cleach","year":"2012","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.disamonth.2022.101349_bib0010","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1111\/j.1601-0825.2008.01441.x","article-title":"Oral lichen planus: controversies surrounding malignant transformation","volume":"14","author":"Gonzalez-Moles","year":"2008","journal-title":"Oral Dis"},{"key":"10.1016\/j.disamonth.2022.101349_bib0011","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.oraloncology.2019.07.012","article-title":"Malignant transformation risk of oral lichen planus: a systematic review and comprehensive meta-analysis","volume":"96","author":"Gonz\u00e1lez-Moles","year":"2019","journal-title":"Oral Oncol"},{"issue":"6","key":"10.1016\/j.disamonth.2022.101349_bib0012","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/j.tripleo.2009.02.020","article-title":"Correlation between clinical and histopathologic diagnoses of oral lichen planus based on modified WHO diagnostic criteria","volume":"107","author":"Rad","year":"2009","journal-title":"Oral Surgery Oral Med Oral Pathol Oral Radiol Endodontol"},{"issue":"9","key":"10.1016\/j.disamonth.2022.101349_bib0013","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1034\/j.1600-0714.2003.00125.x","article-title":"Lack of clinicopathologic correlation in the diagnosis of oral lichen planus based on the presently available diagnostic criteria and suggestions for modifications","volume":"32","author":"Van Der Meij","year":"2003","journal-title":"J Oral Pathol Med"},{"issue":"1","key":"10.1016\/j.disamonth.2022.101349_bib0014","doi-asserted-by":"crossref","first-page":"45","DOI":"10.14219\/jada.2013.10","article-title":"The malignant transformation of oral lichen planus and oral lichenoid lesions","volume":"145","author":"Fitzpatrick","year":"2014","journal-title":"J Am Dent Assoc"},{"issue":"5","key":"10.1016\/j.disamonth.2022.101349_bib0015","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1111\/j.1365-2133.2012.10821.x","article-title":"Interventions for treating oral lichen planus: a systematic review","volume":"166","author":"Lodi","year":"2012","journal-title":"Br J Dermatol"},{"issue":"1","key":"10.1016\/j.disamonth.2022.101349_bib0016","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.tripleo.2004.06.077","article-title":"Current controversies in oral lichen planus: report of an international consensus meeting. Part 1. Viral infections and etiopathogenesis","volume":"100","author":"Lodi","year":"2005","journal-title":"Oral Surg. Oral Med Oral Pathol Oral Radiol Endodontol."},{"issue":"4","key":"10.1016\/j.disamonth.2022.101349_bib0017","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1111\/j.1365-2133.2007.08106.x","article-title":"A scoring system for mucosal disease severity with special reference to oral lichen planus","volume":"157","author":"Escudier","year":"2007","journal-title":"Br J Dermatol"},{"issue":"4","key":"10.1016\/j.disamonth.2022.101349_bib0018","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1054\/bjom.2000.0335","article-title":"Oral lichen planus: a review","volume":"38","author":"Mollaoglu","year":"2000","journal-title":"Br J Oral Maxillofac Surg"},{"issue":"9","key":"10.1016\/j.disamonth.2022.101349_bib0019","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1016\/j.archoralbio.2013.04.004","article-title":"Oral lichen planus: focus on etiopathogenesis","volume":"58","author":"Payeras","year":"2013","journal-title":"Arch Oral Biol"},{"issue":"4","key":"10.1016\/j.disamonth.2022.101349_bib0020","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1159\/000051777","article-title":"Anxiety and depression as risk factors for oral lichen planus","volume":"203","author":"Garc\u00eda-Pola Vallejo","year":"2001","journal-title":"Dermatology"},{"issue":"6","key":"10.1016\/j.disamonth.2022.101349_bib0021","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1034\/j.1601-0825.2003.00960.x","article-title":"The evaluation of anxiety and salivary cortisol levels in patients with oral lichen planus","volume":"9","author":"Koray","year":"2003","journal-title":"Oral Dis"},{"issue":"10","key":"10.1016\/j.disamonth.2022.101349_bib0022","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1111\/j.1600-051X.2005.00829.x","article-title":"Psychological profile in oral lichen planus","volume":"32","author":"Ivanovski","year":"2005","journal-title":"J Clin Periodontol"},{"key":"10.1016\/j.disamonth.2022.101349_bib0023","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.oraloncology.2017.05.013","article-title":"Oral lichenoid dysplasia and exophytic oral verrucous hyperplasia: mythical entities of oral pathology","volume":"70","author":"Thirumal Raj","year":"2017","journal-title":"Oral Oncol"},{"key":"10.1016\/j.disamonth.2022.101349_bib0024","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.oraloncology.2017.06.017","article-title":"Formulating a clinicopathological algorithm for oral lichenoid dysplasia and related lesions","volume":"71","author":"Thirumal Raj","year":"2017","journal-title":"Oral Oncol"},{"key":"10.1016\/j.disamonth.2022.101349_bib0025","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.oraloncology.2017.10.003","article-title":"Diagnostic flaws in oral lichen planus and related lesions","volume":"74","author":"Raj","year":"2017","journal-title":"Oral Oncol"},{"key":"10.1016\/j.disamonth.2022.101349_bib0026","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.mehy.2018.08.011","article-title":"True nature of mild epithelial dysplasia in oral lichenoid mucositis \u2013 is it a reactionary change to the sub-epithelial inflammation or represents true malignant potential? A hypothesis","volume":"120","author":"Raj","year":"2018","journal-title":"Med Hypotheses"},{"issue":"4","key":"10.1016\/j.disamonth.2022.101349_bib0027","doi-asserted-by":"crossref","first-page":"3076","DOI":"10.21037\/tcr.2020.01.51","article-title":"The natural history of oral mucosal lesions with both lichenoid and epithelial dysplastic features: a systematic review","volume":"9","author":"Raj","year":"2020","journal-title":"Transl Cancer Res"},{"issue":"1","key":"10.1016\/j.disamonth.2022.101349_bib0028","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/s10103-012-1153-9","article-title":"Clinical assessment of the efficacy of photodynamic therapy in the treatment of oral lichen planus","volume":"28","author":"Sobaniec","year":"2013","journal-title":"Lasers Med Sci"},{"issue":"3","key":"10.1016\/j.disamonth.2022.101349_bib0029","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1111\/phpp.12371","article-title":"Photodynamic therapy in the treatment of symptomatic oral lichen planus: a systematic review","volume":"34","author":"Akram","year":"2018","journal-title":"Photodermatol Photoimmunol Photomed"},{"key":"10.1016\/j.disamonth.2022.101349_bib0030","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.pdpdt.2017.04.014","article-title":"Evaluation of photodynamic therapy in treatment of oral erosive lichen planus in comparison with topically applied corticosteroids","volume":"19","author":"Mostafa","year":"2017","journal-title":"Photodiagnosis Photodyn Ther"},{"key":"10.1016\/j.disamonth.2022.101349_bib0031","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.pdpdt.2017.06.002","article-title":"Comparing clinical effects of photodynamic therapy as a novel method with topical corticosteroid for treatment of oral lichen planus","volume":"20","author":"Bakhtiari","year":"2017","journal-title":"Photodiagnosis Photodyn Ther"},{"issue":"6","key":"10.1016\/j.disamonth.2022.101349_bib0032","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1136\/annrheumdis-2013-203305","article-title":"Primary Sj\u00f6gren's syndrome and malignancy risk: a systematic review and meta-analysis","volume":"73","author":"Liang","year":"2014","journal-title":"Ann Rheum Dis"},{"issue":"jun14 1","key":"10.1016\/j.disamonth.2022.101349_bib0033","doi-asserted-by":"crossref","first-page":"e3821","DOI":"10.1136\/bmj.e3821","article-title":"Primary Sjogren syndrome","volume":"344","author":"Ramos-Casals","year":"2012","journal-title":"BMJ"},{"issue":"20","key":"10.1016\/j.disamonth.2022.101349_bib0034","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1001\/archinte.165.20.2337","article-title":"The risk of lymphoma development in autoimmune diseases","volume":"165","author":"Zintzaras","year":"2005","journal-title":"Arch Intern Med"},{"issue":"3","key":"10.1016\/j.disamonth.2022.101349_bib0035","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/j.rdc.2020.05.004","article-title":"Sj\u00f6gren syndrome and cancer","volume":"46","author":"Igoe","year":"2020","journal-title":"Rheum Dis Clin North Am"},{"issue":"8","key":"10.1016\/j.disamonth.2022.101349_bib0036","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1093\/rheumatology\/kei281","article-title":"Incidence of cancer in a cohort of patients with primary Sj\u00f6gren's syndrome","volume":"45","author":"Lazarus","year":"2006","journal-title":"Rheumatology"},{"issue":"3","key":"10.1016\/j.disamonth.2022.101349_bib0037","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1093\/rheumatology\/kep404","article-title":"Incidence of malignancy in primary Sjogren's syndrome in a Chinese cohort","volume":"49","author":"Zhang","year":"2010","journal-title":"Rheumatology"},{"issue":"4","key":"10.1016\/j.disamonth.2022.101349_bib0038","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1002\/art.39518","article-title":"Rheumatoid factor and disease activity are independent predictors of lymphoma in primary Sj\u00f6gren's syndrome","volume":"68","author":"Nocturne","year":"2016","journal-title":"Arthritis Rheumatol"},{"issue":"5","key":"10.1016\/j.disamonth.2022.101349_bib0039","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1097\/MD.0b013e3181b76ab5","article-title":"Hematologic manifestations and predictors of lymphoma development in primary Sj\u00f6gren syndrome","volume":"88","author":"Baimpa","year":"2009","journal-title":"Medicine (Baltimore)"},{"issue":"1","key":"10.1016\/j.disamonth.2022.101349_bib0040","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/MD.0b013e31824125e4","article-title":"Prognosis and outcome of non-Hodgkin lymphoma in primary Sj\u00f6gren syndrome","volume":"91","author":"Voulgarelis","year":"2012","journal-title":"Medicine (Baltimore)"},{"issue":"2","key":"10.1016\/j.disamonth.2022.101349_bib0041","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.semarthrit.2013.03.001","article-title":"Clinical features distinguishing lymphoma development in primary Sj\u00f6gren\u2019s syndrome\u2014a retrospective cohort study","volume":"43","author":"Risselada","year":"2013","journal-title":"Semin Arthritis Rheum"},{"issue":"7","key":"10.1016\/j.disamonth.2022.101349_bib0042","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/j.autrev.2018.02.003","article-title":"Cytokine markers of B lymphocytes in minor salivary gland infiltrates in Sj\u00f6gren's syndrome","volume":"17","author":"Navarro-Mendoza","year":"2018","journal-title":"Autoimmun Rev"},{"issue":"1","key":"10.1016\/j.disamonth.2022.101349_bib0043","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1186\/s13045-017-0464-5","article-title":"Characterization and risk estimate of cancer in patients with primary Sj\u00f6gren syndrome","volume":"10","author":"Brito-Zer\u00f3n","year":"2017","journal-title":"J Hematol Oncol"},{"issue":"3","key":"10.1016\/j.disamonth.2022.101349_bib0044","first-page":"150","article-title":"The evaluation of disease activity in Sj\u00f6gren's syndrome based on the degree of MALT involvement: glandular swelling and cryoglobulinaemia compared to ESSDAI in a cohort study","volume":"36","author":"De Vita","year":"2018","journal-title":"Clin Exp Rheumatol"},{"issue":"3","key":"10.1016\/j.disamonth.2022.101349_bib0045","first-page":"102","article-title":"How immunological profile drives clinical phenotype of primary Sj\u00f6gren's syndrome at diagnosis: analysis of 10,500 patients (Sj\u00f6gren big data project)","volume":"36","author":"Brito-Zer\u00f3n","year":"2018","journal-title":"Clin Exp Rheumatol"},{"issue":"3","key":"10.1016\/j.disamonth.2022.101349_bib0046","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1191\/096120398678920019","article-title":"Young onset of primary Sj\u00f6gren's syndrome: clinical and immunological characteristics","volume":"7","author":"Ramos-Casals","year":"1998","journal-title":"Lupus"},{"issue":"8","key":"10.1016\/j.disamonth.2022.101349_bib0047","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1177\/0961203319857132","article-title":"Prognostic markers of lymphoma development in primary Sj\u00f6gren syndrome","volume":"28","author":"Retamozo","year":"2019","journal-title":"Lupus"},{"issue":"25","key":"10.1016\/j.disamonth.2022.101349_bib0048","doi-asserted-by":"crossref","first-page":"e3766","DOI":"10.1097\/MD.0000000000003766","article-title":"Predicting the risk for lymphoma development in Sjogren syndrome","volume":"95","author":"Fragkioudaki","year":"2016","journal-title":"Medicine (Baltimore)"},{"issue":"3","key":"10.1016\/j.disamonth.2022.101349_bib0049","first-page":"198","article-title":"Phenotyping Sj\u00f6gren's syndrome: towards a personalised management of the disease","volume":"36","author":"Brito-Zer\u00f3n","year":"2018","journal-title":"Clin Exp Rheumatol"},{"issue":"4","key":"10.1016\/j.disamonth.2022.101349_bib0050","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1007\/s00296-020-04529-0","article-title":"Serum immunoglobulin G4 in Sj\u00f6gren's syndrome: a pilot study","volume":"40","author":"Ma\u015bli\u0144ska","year":"2020","journal-title":"Rheumatol Int"},{"issue":"2","key":"10.1016\/j.disamonth.2022.101349_bib0051","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1136\/annrheumdis-2014-206418","article-title":"Systemic activity and mortality in primary Sj\u00f6gren syndrome: predicting survival using the EULAR-SS disease Activity Index (ESSDAI) in 1045 patients","volume":"75","author":"Brito-Zer\u00f3n","year":"2016","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"10.1016\/j.disamonth.2022.101349_bib0052","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1002\/acr.21887","article-title":"Risk of non-Hodgkin's lymphoma in primary Sj\u00f6gren's syndrome: a population-based study","volume":"65","author":"Johnsen","year":"2013","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"3","key":"10.1016\/j.disamonth.2022.101349_bib0053","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1002\/art.10221","article-title":"Long-term risk of mortality and lymphoproliferative disease and predictive classification of primary Sj\u00f6gren's syndrome","volume":"46","author":"Ioannidis","year":"2002","journal-title":"Arthritis Rheum"},{"issue":"10","key":"10.1016\/j.disamonth.2022.101349_bib0054","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1093\/annonc\/mdu365","article-title":"Autoimmune diseases associated with non-Hodgkin lymphoma: a nationwide cohort study","volume":"25","author":"Fallah","year":"2014","journal-title":"Ann Oncol"},{"issue":"819","key":"10.1016\/j.disamonth.2022.101349_bib0055","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1259\/0007-1285-69-819-272","article-title":"Pseudotumoral brain lesion as the presenting feature of sarcoidosis","volume":"69","author":"Grand","year":"1996","journal-title":"Br J Radiol"},{"issue":"10","key":"10.1016\/j.disamonth.2022.101349_bib0056","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.3174\/ajnr.A1204","article-title":"Primary Sj\u00f6gren syndrome with tumefactive central nervous system involvement: fig 1","volume":"29","author":"Sanahuja","year":"2008","journal-title":"Am J Neuroradiol"},{"issue":"4","key":"10.1016\/j.disamonth.2022.101349_bib0057","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.semarthrit.2010.06.005","article-title":"Atypical neurologic complications in patients with primary Sj\u00f6gren's syndrome: report of 4 cases","volume":"40","author":"Michel","year":"2011","journal-title":"Semin Arthritis Rheum"},{"issue":"5","key":"10.1016\/j.disamonth.2022.101349_bib0058","first-page":"217","article-title":"Increased risk of malignancy in patients with systemic lupus erythematosus","volume":"46","author":"Ramsey-Goldman","year":"1998","journal-title":"J Investig Med"},{"issue":"10","key":"10.1016\/j.disamonth.2022.101349_bib0059","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1093\/rheumatology\/39.10.1147","article-title":"Is there an association of malignancy with systemic lupus erythematosus? An analysis of 276 patients under long-term review","volume":"39","author":"Sultan","year":"2000","journal-title":"Rheumatology"},{"issue":"6","key":"10.1016\/j.disamonth.2022.101349_bib0060","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1002\/art.1780390625","article-title":"Malignancy in systemic lupus erythematosus","volume":"39","author":"Abu-Shakra","year":"1996","journal-title":"Arthritis Rheum"},{"issue":"6","key":"10.1016\/j.disamonth.2022.101349_bib0061","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1191\/096120301678646128","article-title":"Systemic lupus erythematosus and the risk of malignancy","volume":"10","author":"Cibere","year":"2001","journal-title":"Lupus"},{"issue":"4","key":"10.1016\/j.disamonth.2022.101349_bib0062","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1136\/ard.51.4.437","article-title":"Increased risk of cancer in patients with systemic lupus erythematosus","volume":"51","author":"Pettersson","year":"1992","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"10.1016\/j.disamonth.2022.101349_bib0063","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.3899\/jrheum.170179","article-title":"Malignancy in pediatric-onset systemic lupus erythematosus","volume":"44","author":"Bernatsky","year":"2017","journal-title":"J Rheumatol"},{"issue":"7","key":"10.1016\/j.disamonth.2022.101349_bib0064","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1191\/096120301678416079","article-title":"Malignancies during follow-up in an epidemiologically defined systemic lupus erythematosus inception cohort in southern Sweden","volume":"10","author":"Nived","year":"2001","journal-title":"Lupus"},{"issue":"4","key":"10.1016\/j.disamonth.2022.101349_bib0065","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/s11926-002-0045-6","article-title":"Malignancy and systemic lupus erythematosus","volume":"4","author":"Bernatsky","year":"2002","journal-title":"Curr Rheumatol Rep"},{"issue":"11","key":"10.1016\/j.disamonth.2022.101349_bib0066","doi-asserted-by":"crossref","first-page":"2743","DOI":"10.1002\/eji.1830211114","article-title":"Major histocompatibility complex controls clonal proliferation of CD5+ B cells in H-2-congenic New Zealand mice: a model for B cell chronic lymphocytic leukemia and autoimmune disease","volume":"21","author":"Okada","year":"1991","journal-title":"Eur J Immunol"},{"issue":"2","key":"10.1016\/j.disamonth.2022.101349_bib0067","doi-asserted-by":"crossref","first-page":"117","DOI":"10.3109\/08916939908994055","article-title":"Reduced in vitro production of interferon-gamma, interleukin-4 and interleukin-12 and increased production of interleukin-6, interleukin-10 and tumour necrosis factor-alpha in systemic lupus erythematosus. Weak correlations of cytokine production with dis","volume":"31","author":"Jones","year":"1999","journal-title":"Autoimmunity"},{"issue":"1","key":"10.1016\/j.disamonth.2022.101349_bib0068","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1006\/gyno.2001.6235","article-title":"Interleukin-6 in cervical cancer: the relationship with vascular endothelial growth factor","volume":"82","author":"Wei","year":"2001","journal-title":"Gynecol Oncol"},{"issue":"6","key":"10.1016\/j.disamonth.2022.101349_bib0069","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1016\/S0090-4295(01)01405-4","article-title":"Plasma levels of interleukin-6 and its soluble receptor are associated with prostate cancer progression and metastasis","volume":"58","author":"Shariat","year":"2001","journal-title":"Urology"},{"issue":"5-6","key":"10.1016\/j.disamonth.2022.101349_bib0070","doi-asserted-by":"crossref","first-page":"563","DOI":"10.3109\/10428199809057568","article-title":"High serum interleukin-6 levels correlate with a shorter failure-free survival in indolent lymphoma","volume":"30","author":"Fayad","year":"1998","journal-title":"Leuk Lymphoma"},{"issue":"10","key":"10.1016\/j.disamonth.2022.101349_bib0071","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1007\/s000180050238","article-title":"A role for growth hormone and prolactin in leukaemia and lymphoma?","volume":"54","author":"Hooghe","year":"1998","journal-title":"Cell Mol Life Sci C"},{"issue":"3","key":"10.1016\/j.disamonth.2022.101349_bib0072","first-page":"292","article-title":"The roles of prolactin, growth hormone, insulin-like growth factor-i, and thyroid hormones in lymphocyte development and function: insights from genetic models of hormone and hormone receptor deficiency","volume":"21","author":"Dorshkind","year":"2000","journal-title":"Endocr Rev"},{"key":"10.1016\/j.disamonth.2022.101349_bib0073","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S1096-6374(99)80025-2","article-title":"The role of growth hormone and insulin-like growth factor I in the regulation of apoptosis","volume":"9","author":"Isgaard","year":"1999","journal-title":"Growth Horm IGF Res"},{"issue":"10","key":"10.1016\/j.disamonth.2022.101349_bib0074","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1007\/s000180050239","article-title":"Prolactin, growth hormone and the immune system in humans","volume":"54","author":"Velkeniers","year":"1998","journal-title":"Cell Mol Life Sci C"},{"issue":"3","key":"10.1016\/j.disamonth.2022.101349_bib0075","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.berh.2017.09.013","article-title":"A review on SLE and malignancy","volume":"31","author":"Choi","year":"2017","journal-title":"Best Pract Res Clin Rheumatol"},{"issue":"7","key":"10.1016\/j.disamonth.2022.101349_bib0076","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1038\/nrrheum.2016.23","article-title":"DNA-damaging autoantibodies and cancer: the lupus butterfly theory","volume":"12","author":"Noble","year":"2016","journal-title":"Nat Rev Rheumatol"},{"issue":"5","key":"10.1016\/j.disamonth.2022.101349_bib0077","first-page":"217","article-title":"Increased risk of malignancy in patients with systemic lupus erythematosus","volume":"46","author":"Ramsey-Goldman","year":"1998","journal-title":"J Investig Med"},{"issue":"6","key":"10.1016\/j.disamonth.2022.101349_bib0078","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1191\/096120301678646100","article-title":"Double trouble: are lupus and malignancy associated?","volume":"10","author":"Ramsey-Goldman","year":"2001","journal-title":"Lupus"},{"issue":"7","key":"10.1016\/j.disamonth.2022.101349_bib0079","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1177\/096120330000900711","article-title":"Increased cervical dysplasia in intravenous cyclophosphamidetreated patients with SLE: a preliminary study","volume":"9","author":"Bateman","year":"2000","journal-title":"Lupus"},{"issue":"4","key":"10.1016\/j.disamonth.2022.101349_bib0080","first-page":"200","article-title":"Primary intracerebral lymphoma in systemic lupus erythematosus treated with immunosuppressives","volume":"8","author":"Cras","year":"1989","journal-title":"Clin Neuropathol"},{"issue":"6323","key":"10.1016\/j.disamonth.2022.101349_bib0081","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1136\/bmj.284.6323.1160","article-title":"Cyclophosphamide treatment of systemic lupus erythematosus: risk of bladder cancer exceeds benefit","volume":"284","author":"Elliott","year":"1982","journal-title":"BMJ"},{"issue":"1","key":"10.1016\/j.disamonth.2022.101349_bib0082","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1136\/ard.38.1.94","article-title":"Reticulum cell sarcoma in azathioprine-treated systemic lupus erythematosus","volume":"38","author":"Hehir","year":"1979","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"10.1016\/j.disamonth.2022.101349_bib0083","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1159\/000186790","article-title":"Bladder cancer after cyclophosphamide therapy for lupus nephritis","volume":"60","author":"Ortiz","year":"1992","journal-title":"Nephron"},{"issue":"1","key":"10.1016\/j.disamonth.2022.101349_bib0084","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S0022-5347(17)39886-5","article-title":"Bladder leiomyosarcoma following cyclophosphamide therapy for lupus nephritis","volume":"143","author":"Thrasher","year":"1990","journal-title":"J Urol"},{"issue":"4","key":"10.1016\/j.disamonth.2022.101349_bib0085","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.berh.2008.12.007","article-title":"Malignancy in systemic lupus erythematosus: what have we learned?","volume":"23","author":"Bernatsky","year":"2009","journal-title":"Best Pract Res Clin Rheumatol"},{"issue":"6","key":"10.1016\/j.disamonth.2022.101349_bib0086","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1136\/ard.2006.067777","article-title":"Antimalarials may influence the risk of malignancy in systemic lupus erythematosus","volume":"66","author":"Ruiz-Irastorza","year":"2007","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"10.1016\/j.disamonth.2022.101349_bib0087","first-page":"2551","article-title":"Prevalence of factors influencing cancer risk in women with lupus: social habits, reproductive issues, and obesity","volume":"29","author":"Bernatsky","year":"2002","journal-title":"J Rheumatol"},{"issue":"4","key":"10.1016\/j.disamonth.2022.101349_bib0088","first-page":"435","article-title":"Detection and modification of risk factors for coronary artery disease in patients with systemic lupus erythematosus: a quality improvement study","volume":"16","author":"Bruce","year":"1998","journal-title":"Clin Exp Rheumatol"},{"issue":"6","key":"10.1016\/j.disamonth.2022.101349_bib0089","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1001\/jama.1995.03520300065039","article-title":"Ovarian cancer. Screening, treatment, and follow-up. NIH consensus development panel on ovarian cancer","volume":"273","year":"1995","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.disamonth.2022.101349_bib0090","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1093\/rheumatology\/32.3.227","article-title":"Contraceptive practice in women with systemic lupus erythematosus","volume":"32","author":"Julkunen","year":"1993","journal-title":"Rheumatology"},{"issue":"5","key":"10.1016\/j.disamonth.2022.101349_bib0091","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/0002-9343(92)90578-Y","article-title":"Risk factors for coronary artery disease in patients with systemic lupus erythematosus","volume":"93","author":"Petri","year":"1992","journal-title":"Am J Med"},{"issue":"6","key":"10.1016\/j.disamonth.2022.101349_bib0092","first-page":"796","article-title":"Combination oral contraceptive use and the risk of endometrial cancer. The Cancer and Steroid Hormone Study of the Centers for Disease Control and the National Institute of Child Health and Human Development","volume":"257","year":"1987","journal-title":"JAMA"},{"issue":"7","key":"10.1016\/j.disamonth.2022.101349_bib0093","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1111\/j.1365-2133.1969.tb16024.x","article-title":"Granular deposits of immunoglobulins in the skin of patients with dermatitis herpetiformis. An immunofluorescent study","volume":"81","author":"MEER","year":"1969","journal-title":"Br J Dermatol"},{"issue":"8","key":"10.1016\/j.disamonth.2022.101349_bib0094","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1001\/archderm.1996.03890320060010","article-title":"Deposition of granular IgA relative to clinical lesions in dermatitis herpetiformis","volume":"132","author":"Zone","year":"1996","journal-title":"Arch Dermatol"},{"issue":"5","key":"10.1016\/j.disamonth.2022.101349_bib0095","doi-asserted-by":"crossref","first-page":"416","DOI":"10.3109\/07853899809002482","article-title":"Dermatitis herpetiformis: coeliac disease of the skin","volume":"30","author":"Reunala","year":"1998","journal-title":"Ann Med"},{"issue":"4","key":"10.1016\/j.disamonth.2022.101349_bib0096","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1136\/gut.38.4.528","article-title":"Malignancy and survival in dermatitis herpetiformis: a comparison with coeliac disease","volume":"38","author":"Collin","year":"1996","journal-title":"Gut"},{"issue":"2","key":"10.1016\/j.disamonth.2022.101349_bib0097","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1111\/j.1365-2133.1993.tb03516.x","article-title":"Mortality and cancer incidence in patients with dermatitis herpetiformis: a cohort study","volume":"129","author":"Swerdlow","year":"1993","journal-title":"Br J Dermatol"},{"issue":"6358","key":"10.1016\/j.disamonth.2022.101349_bib0098","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1136\/bmj.286.6358.16","article-title":"Increased incidence of malignancy in dermatitis herpetiformis","volume":"286","author":"Leonard","year":"1983","journal-title":"BMJ"},{"issue":"6920","key":"10.1016\/j.disamonth.2022.101349_bib0099","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1136\/bmj.308.6920.13","article-title":"Risk of lymphoma in patients with dermatitis herpetiformis","volume":"308","author":"Sigurgeisson","year":"1994","journal-title":"BMJ"},{"issue":"5","key":"10.1016\/j.disamonth.2022.101349_bib0100","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1111\/1523-1747.ep12486805","article-title":"Molecular analysis of HLA DP and DQ genes associated with dermatitis herpetiformis","volume":"97","author":"Fronek","year":"1991","journal-title":"J Invest Dermatol"},{"issue":"1","key":"10.1016\/j.disamonth.2022.101349_bib0101","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.clindermatol.2011.03.010","article-title":"Dermatitis herpetiformis","volume":"30","author":"K\u00e1rp\u00e1ti","year":"2012","journal-title":"Clin Dermatol"},{"issue":"6","key":"10.1016\/j.disamonth.2022.101349_bib0102","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.dld.2006.03.002","article-title":"Malignancies and mortality in patients with coeliac disease and dermatitis herpetiformis: 30-year population-based study","volume":"38","author":"Viljamaa","year":"2006","journal-title":"Dig Liver Dis"},{"issue":"3","key":"10.1016\/j.disamonth.2022.101349_bib0103","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1136\/gut.30.3.333","article-title":"Malignancy in coeliac disease\u2013effect of a gluten free diet","volume":"30","author":"Holmes","year":"1989","journal-title":"Gut"},{"issue":"1","key":"10.1016\/j.disamonth.2022.101349_bib0104","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1046\/j.1523-1747.1999.00627.x","article-title":"Antibodies to tissue transglutaminase as serologic markers in patients with dermatitis herpetiformis","volume":"113","author":"Dieterich","year":"1999","journal-title":"J Invest Dermatol"},{"issue":"6","key":"10.1016\/j.disamonth.2022.101349_bib0105","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1084\/jem.20011299","article-title":"Epidermal transglutaminase (TGase 3) is the autoantigen of dermatitis herpetiformis","volume":"195","author":"S\u00e1rdy","year":"2002","journal-title":"J Exp Med"},{"issue":"11","key":"10.1016\/j.disamonth.2022.101349_bib0106","doi-asserted-by":"crossref","first-page":"2728","DOI":"10.1038\/jid.2009.142","article-title":"IgA anti-epidermal transglutaminase antibodies in dermatitis herpetiformis and pediatric celiac disease","volume":"129","author":"Jaskowski","year":"2009","journal-title":"J Invest Dermatol"},{"issue":"1","key":"10.1016\/j.disamonth.2022.101349_bib0107","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1111\/j.1468-3083.2004.01132.x","article-title":"complement and epidermal transglutaminase deposition in the cutaneous vessels in dermatitis herpetiformis","volume":"19","author":"Preisz","year":"2005","journal-title":"J Eur Acad Dermatology Venereol"},{"issue":"6","key":"10.1016\/j.disamonth.2022.101349_bib0108","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1038\/sj.jid.5700277","article-title":"Cutaneous endothelial cell activation in normal skin of patients with dermatitis herpetiformis associated with increased serum levels of IL-8, sE-selectin, and TNF-\u03b1","volume":"126","author":"Hall","year":"2006","journal-title":"J Invest Dermatol"},{"issue":"6","key":"10.1016\/j.disamonth.2022.101349_bib0109","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/S0738-081X(00)00185-1","article-title":"Linear IgA bullous dermatosis","volume":"19","author":"Guide","year":"2001","journal-title":"Clin Dermatol"},{"issue":"5","key":"10.1016\/j.disamonth.2022.101349_bib0110","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1111\/1523-1747.ep12876246","article-title":"Cutaneous IgA deposits in bullous diseases function as ligands to mediate adherence of activated neutrophils","volume":"94","author":"Hendrix","year":"1990","journal-title":"J Invest Dermatol"},{"issue":"3","key":"10.1016\/j.disamonth.2022.101349_bib0111","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.det.2011.03.013","article-title":"Linear IgA disease: clinical presentation, diagnosis, and pathogenesis","volume":"29","author":"Venning","year":"2011","journal-title":"Dermatol Clin"},{"issue":"1","key":"10.1016\/j.disamonth.2022.101349_bib0112","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1111\/1523-1747.ep12514565","article-title":"Small intestinal biopsies and HLA types in dermatitis herpetiformis patients with granular and linear IgA skin deposits","volume":"74","author":"Lawley","year":"1980","journal-title":"J Invest Dermatol"},{"issue":"1","key":"10.1016\/j.disamonth.2022.101349_bib0113","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1177\/014107688708000118","article-title":"Linear IgA disease and oesophageal carcinoma","volume":"80","author":"Green","year":"1987","journal-title":"J R Soc Med"},{"issue":"4","key":"10.1016\/j.disamonth.2022.101349_bib0114","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1111\/j.1365-2133.1990.tb01448.x","article-title":"Linear IgA disease of adults: association with lymphoproliferative malignancy and possible role of other triggering factors","volume":"123","author":"Godfrey","year":"2006","journal-title":"Br J Dermatol"},{"issue":"6","key":"10.1016\/j.disamonth.2022.101349_bib0115","first-page":"354","article-title":"Linear IgA bullous disease in a patient with transitional cell carcinoma of the bladder","volume":"38","author":"Sekula","year":"1986","journal-title":"Cutis"},{"issue":"2","key":"10.1016\/j.disamonth.2022.101349_bib0116","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1111\/j.1365-2133.1997.tb14909.x","article-title":"Linear IgA disease in a patient with bladder carcinoma","volume":"136","author":"R\u00f3denas","year":"1997","journal-title":"Br J Dermatol"},{"issue":"2","key":"10.1016\/j.disamonth.2022.101349_bib0117","doi-asserted-by":"crossref","first-page":"123","DOI":"10.2340\/0001555563123128","article-title":"Linear IgA dermatosis: a study of ten adult patients","volume":"63","author":"Mobacken","year":"1983","journal-title":"Acta Derm Venereol"},{"issue":"2","key":"10.1016\/j.disamonth.2022.101349_bib0118","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/S0190-9622(08)80303-9","article-title":"Linear IgA dermatosis and thyroid carcinoma","volume":"26","author":"Lacour","year":"1992","journal-title":"J Am Acad Dermatol"}],"container-title":["Disease-a-Month"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0011502922000335?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0011502922000335?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T01:03:14Z","timestamp":1757898194000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0011502922000335"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":118,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["S0011502922000335"],"URL":"https:\/\/doi.org\/10.1016\/j.disamonth.2022.101349","relation":{},"ISSN":["0011-5029"],"issn-type":[{"type":"print","value":"0011-5029"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Oral immune-mediated disorders with malignant potential\/association: An overview","name":"articletitle","label":"Article Title"},{"value":"Disease-a-Month","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.disamonth.2022.101349","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"101349"}}